P-318. HIV Pre-Exposure Prophylaxis Eligibility and Feasibility in the Health Frontiers in Tijuana Network

Abstract Background The Tijuana-California border is a metroplex that integrates multiple risk factors for HIV transmission across borders. However, awareness and uptake of pre-exposure prophylaxis (PrEP) remains low in the region. Health Frontiers in Tijuana (HFiT), a partnership between United States and Tijuana academic training sites for marginalized populations, may serve as an optimal location for PrEP delivery.Table 1Demographic Characteristics of PatientsTable 2HIV Pre-Exposure Prophylaxis Questionnaire: Demographics Methods We assessed risk factors for HIV transmission among electronic medical record patient encounters (n=2390) from January 2022 to December 2024 (Table 1). Anonymized surveys were conducted from January through April 2025 (n = 23) to assess PrEP delivery capacity among HFiT-affiliated physicians and pharmacists (Tables 2 and 3). This survey was derived from prior questionnaires on PrEP awareness in health providers.Table 3HIV Pre-Exposure Questionnaire: Barriers and FacilitatorsTable 4PrEP Care Continuum Results HIV prevalence in this population (3.5%) was over 18 times the estimated national HIV prevalence in Mexico, and more than four times above Baja California background rates. Female gender, use of recreational drugs, and presence of comorbid sexually transmitted infections (p< 0.001) were associated with increased risk for HIV positive test. This data suggests a high number of eligible patients for PrEP. A substantial number of survey respondees (87.6%) felt that PrEP was of high utility in HFiT’s patient population. Both physicians (68.8%) and pharmacists (100%) had an adequate understanding of which patients were eligible for PrEP. Education gaps regarding PrEP eligibility were seen in junior providers such as medical students, but less so in senior providers such as residents and attending physicians. Barriers to PrEP adoption appeared feasible to overcome. Provider perception regarding insurance ineligibility (79%) has been mitigated by recent approval of tenofovir disoproxil fumarate-emtricitabine in Mexican public insurance. Concerns about staffing (35%) and lab barriers (60%) can also be mitigated, through provider education materials and identification of discrete sites in the PrEP care continuum (Table 4). Conclusion Overall, high eligibility for PrEP exists in HFiT’s population. Future uptake interventions at this site can lessen HIV spread in Tijuana, including development of a PrEP care continuum for the Tijuana metropolitan area. Disclosures All Authors: No reported disclosures